Arbutus and qilu pharmaceutical enter into an exclusive licensing agreement and strategic partnership to develop and commercialize ab-729 in mainland china, hong kong, macau and taiwan

Qilu pharmaceutical, one of the leading pharmaceutical companies in china, becomes strategic partner to provide development, manufacturing and commercialization expertise for the mainland china, hong kong, macau and taiwan markets
ABUS Ratings Summary
ABUS Quant Ranking